Fool - Investing News
21 Apr 2026, 19:26 UTC · 27w ago
Verdict
Headline takes no side. We score VRDN −0.80 across four claims — strongly bearish.
−0.80strongly bearish
More negative than 92% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Amgen's Phase 3 results for a subcutaneous version of Tepezza showed a 77% proptosis response rate, numerically superior to Viridian's elegrobart results of 54% to 63%.
So whatDirect competitive failure or inferiority in clinical efficacy for a lead candidate typically triggers significant valuation drops for biotech firms.
More negative than 99% of claims this week
Viridian's Phase 3 REVEAL-1 data for elegrobart met primary endpoints but showed limited inflammation improvement and reports of tinnitus.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More negative than 95% of claims this week
Kopp Family Office reduced its stake in Viridian Therapeutics by more than two-thirds during Q1, selling 117,878 shares.
More negative than 79% of claims this week
Viridian reported a net loss of $343 million for full-year 2025, though it maintains a cash position of approximately $875 million.
So whatHigh burn rates are typical for clinical-stage biotech, and the substantial cash cushion mitigates immediate bankruptcy risk.
More negative than 66% of claims this week
Which stocks this story touches
More negative than 92% of ticker scores this week
Shares fell over 50% since March following disappointing Phase 3 data and strong competitive results from a rival.
More positive than 75% of ticker scores this week
Reported Phase 3 results for its subcutaneous Tepezza that showed numerically stronger response rates than Viridian's candidate.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Business Insider
10h ago
Business Insider
10h ago
+68.1%
Price is moving against the score
$24.67 vs $14.68 close before publication (Apr 20) · not market-adjusted
VRDN chart →
